[Experimental study of pBMP/MPTCP in bone defects therapy].
To develop a new substitute of bone graft, which is composed of porcine bone morphogenetic protein (pBMP) and the magnetic porous tricalcium phosphate (MPTCP), we investigated the effects of pBMP/MPTCP (Group A), autologous red bone marrow/porus tricalcium phosphate (BM/PTCP) (Group B), pBMP/PTCP(Group C) on the repair of bone defects created surgically in rabbits. By gross inspection, roentgenography examination, histological examination, immunohistochemistry test of osteocalcim, quantitive histological measurement of new bone formation and biomechanical test, three kinds of substitutes were proved to be biocompatible. Group A induced more new bone formation than other two groups, and showed a better biomechanical function(P < 0.01). It is believed that pBMP/MPTCP has characteristics of strong osteoinductive capacity, good biocompatibility, excellent filling of bone defects and gradual biodegradation.
Yi
W H
WH
Department of Orthopaedics, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Lu
C
C
Zhou
J N
JN
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D051379:Mice; D011817:Rabbits; D011885:Radius Fractures / Q000628:therapy*; D011897:Random Allocation
D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; C018392:tricalcium phosphate